OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

Recent studies have highlighted the therapeutic efficacy of immunotherapy, a class of cancer treatments that utilize the patient’s own immune system to destroy cancerous cells. Within a tumor the presence of a family of negative regulatory molecules, collectively known as “checkpoint inhibitors,” can inhibit T cell function to suppress anti-tumor immunity. Checkpoint inhibitors, such as CTLA-4 and PD-1, attenuate T cell proliferation and cytokine production. Targeted blockade of CTLA-4 or PD-1 with antagonist monoclonal antibodies (mAbs) releases the “brakes” on T cells to boost anti-tumor immunity. Generating optimal “killer” CD8 T cell responses also requires T cell receptor activation plus co-stimulation, which can be provided through ligation of tumor necrosis factor receptor family members, including OX40 (CD134) and 4-1BB (CD137). OX40 is of particular interest as treatment with an activating (agonist) anti-OX40 mAb augments T cell differentiation and cytolytic function leading to enhanced anti-tumor immunity against a variety of tumors. When used as single agents, these drugs can induce potent clinical and immunologic responses in patients with metastatic disease. However, each of these agents only benefits a subset of patients, highlighting the critical need for more effective combinatorial therapeutic strategies. In this review, we will discuss our current understanding of the cellular and molecular mechanisms by which OX40 agonists synergize with checkpoint inhibitor blockade to augment T cell-mediated anti-tumor immunity and the potential opportunities for clinical translation of combinatorial immunotherapeutic strategies.

• Publication year

  2015

• Venue

  Frontiers in Oncology

• Publication date

  2015-02-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fonc.2015.00034PMID 25763356PMCID 4329814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8+ T cells

  2014cited by this paper
• OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

  2014cited by this paper
• The TNF family in T cell differentiation and function--unanswered questions and future directions.

  2014cited by this paper
• Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging

  2014cited by this paper
• PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer

  2014cited by this paper
• T Helper Cells Fate Mapping by Co-stimulatory Molecules and its Functions in Allograft Rejection and Tolerance

  2014cited by this paper
• Orchestrating immune check-point blockade for cancer immunotherapy in combinations.

  2014cited by this paper
• Biochemical Signaling of PD-1 on T Cells and Its Functional Implications

  2014cited by this paper
• CD8+ T Cell–Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

  2014cited by this paper
• Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses

  2014cited by this paper
• Costimulatory TNFR family members in control of viral infection: outstanding questions.

  2014cited by this paper
• Immune modulation for cancer therapy

  2014cited by this paper
• Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer

  2014cited by this paper
• Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

  2014cited by this paper
• PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.

  2014cited by this paper
• Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity

  2013cited by this paper
• Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

  2013cited by this paper
• Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model

  2013cited by this paper
• OX40 is a potent immune-stimulating target in late-stage cancer patients.

  2013influential reference
• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cited by this paper
• Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells

  2013cited by this paper
• TIM-3 Does Not Act as a Receptor for Galectin-9

  2013cited by this paper
• Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

  2013cited by this paper
• Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity.

  2013cited by this paper
• Strength of PD-1 signaling differentially affects T-cell effector functions

  2013cited by this paper
• Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

  2013cited by this paper
• T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.

  2013cited by this paper
• At the Bedside: CTLA‐4‐ and PD‐1‐blocking antibodies in cancer immunotherapy

  2013cited by this paper
• Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients.

  2013cited by this paper
• Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas

  2013cited by this paper
• Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

  2013cited by this paper
• Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity

  2013cited by this paper
• Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored

  2013cited by this paper
• Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

  2013influential reference
• Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

  2013cited by this paper
• PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.

  2013cited by this paper
• NK cell MHC class I specific receptors (KIR): from biology to clinical intervention.

  2012cited by this paper
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

  2012cited by this paper
• Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells.

  2012cited by this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cited by this paper
• A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.

  2012cited by this paper
• Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

  2012cited by this paper
• Combinatorial Immunotherapy

  2012cited by this paper
• CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

  2012cited by this paper
• PD-1 and BTLA and CD8+ T-cell “exhaustion” in cancer

  2012cited by this paper
• The confluence of radiotherapy and immunotherapy

  2012cited by this paper
• Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype

  2012cited by this paper
• An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

  2012cited by this paper
• Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses

  2012cited by this paper
• Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy

  2012cited by this paper
• Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

  2012cited by this paper
• Ligand specificity of Killer cell Immunoglobulin-like Receptors: a brief history of KIR

  2012cited by this paper
• Role of the PD‐1 Pathway in the Immune Response

  2012cited by this paper
• Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies

  2012cited by this paper
• Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• Structure/function of human killer cell immunoglobulin‐like receptors: lessons from polymorphisms, evolution, crystal structures and mutations

  2011cited by this paper
• Intratumor OX40 stimulation inhibits IRF1 expression and IL‐10 production by Treg cells while enhancing CD40L expression by effector memory T cells

  2011cited by this paper
• LAG-3 in Cancer Immunotherapy.

  2011cited by this paper
• Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms

  2011cited by this paper
• Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice.

  2011cited by this paper
• Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

  2011cited by this paper
• Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses

  2011cited by this paper
• Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.

  2011influential reference
• PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

  2011cited by this paper
• Follicular helper CD4 T cells (TFH).

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy

  2011cited by this paper
• Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.

  2010cited by this paper
• Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

  2010cited by this paper
• Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization

  2010cited by this paper
• Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice

  2010cited by this paper
• Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

  2010cited by this paper
• Signaling through OX40 enhances antitumor immunity.

  2010cited by this paper
• Prostate cancer as a model for tumour immunotherapy

  2010cited by this paper
• Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

  2010cited by this paper
• BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

  2010cited by this paper
• Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

  2010cited by this paper
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  2010cited by this paper
• Control of immunity by the TNFR-related molecule OX40 (CD134).

  2010cited by this paper
• Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

  2010cited by this paper
• Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

  2010cited by this paper
• The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.

  2010cited by this paper
• A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Cutting Edge: Lack of High Affinity Competition for Peptide in Polyclonal CD4+ Responses Unmasks IL-4 Production

  2010cited by this paper
• Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

  2010cited by this paper
• Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

  2010cited by this paper
• Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

  2010cited by this paper
• Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1

  2009cited by this paper
• Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

  2009cited by this paper

• Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy

  2026cites this paper
• Combining immune checkpoints with TNFSF agonists: a new horizon for cancer and autoimmune therapies

  2025cites this paper
• Dual targeting OX40 and IL-2 receptor enhances antitumor activity through tumor-infiltrating Treg depletion and CD8+ T-cell proliferation

  2025cites this paper
• Enhanced Antitumor Immunity Through T Cell Activation with Optimized Tandem Double-OX40L mRNAs

  2025cites this paper
• Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma

  2025cites this paper
• Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells

  2025cites this paper
• In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinoma

  2025cites this paper
• Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches

  2025cites this paper
• Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy

  2025cites this paper
• The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology.

  2025cites this paper
• Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes

  2025cites this paper
• SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity

  2024cites this paper
• Soluble Plasma Proteins of Tumor Necrosis Factor and Immunoglobulin Superfamilies Reveal New Insights into Immune Regulation in People with HIV and Opioid Use Disorder

  2024cites this paper
• Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients

  2024cites this paper
• Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

  2024cites this paper
• Making the effect visible – OX40 targeting nanobodies for in vivo imaging of activated T cells

  2024cites this paper
• Establishment and validation of a novel disulfidptosis-related immune checkpoint gene signature in clear cell renal cell carcinoma

  2024cites this paper
• Engineering antibodies with cancer‐associated binding sites

  2024cites this paper
• Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and kill

  2024influential citation
• Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

  2024cites this paper
• Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer

  2023cites this paper
• BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy

  2023cites this paper
• Targeting intracellular and extracellular receptors with nano-to-macroscale biomaterials to activate immune cells.

  2023cites this paper
• Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors

  2023cites this paper
• Physical- and Chemical-Dually ROS-Responsive Nano-in-Gel Platforms with Sequential Release of OX40 Agonist and PD-1 Inhibitor for Augmented Combination Immunotherapy.

  2023cites this paper
• Multiagent Intratumoral Immunotherapy Can Be Effective in A20 Lymphoma Clearance and Generation of Systemic T Cell Immunity

  2023cites this paper
• Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non–small cell lung cancer

  2023cites this paper
• Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

  2023cites this paper
• Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer

  2023cites this paper
• Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives

  2023cites this paper
• Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

  2023cites this paper
• Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

  2023cites this paper
• Comparative evaluation of antitumor effects of TNF superfamily costimulatory ligands delivered by mesenchymal stem cells.

  2023cites this paper
• BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models

  2023cites this paper
• The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress

  2023cites this paper
• Enhanced SARS-CoV-2-Specific CD4+ T Cell Activation and Multifunctionality in Late Convalescent COVID-19 Individuals

  2022cites this paper
• Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance

  2022cites this paper
• Interaction of Radiotherapy and Hyperthermia with the Immune System: a Brief Current Overview

  2022cites this paper
• Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: Unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model

  2022cites this paper
• Emerging Targets in Clear Cell Renal Cell Carcinoma

  2022cites this paper
• Emerging treatment strategies for metastatic triple-negative breast cancer

  2022cites this paper
• Melanoma: An immunotherapy journey from bench to bedside.

  2022cites this paper
• Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors.

  2022cites this paper
• Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions

  2022cites this paper
• Emerging Trends in Immunotherapy for Cancer

  2022cites this paper
• Current Clinical Trial Landscape of OX40 Agonists

  2022cites this paper
• In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways

  2022cites this paper
• PD‐1/PD‐L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity

  2021cites this paper
• Addressing resistance to immune checkpoint inhibitor therapy - an urgent unmet need.

  2021cites this paper
• The role of tumor necrosis factor receptor superfamily member 4 (TNFRSF4) gene expression in diagnosis and prognosis of acute myeloid leukemia

  2021cites this paper
• Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing

  2021cites this paper
• Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies

  2021cites this paper
• Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties

  2021cites this paper
• Have Superagonist Properties Anti-CD40 Antibodies Fused to CD40 Ligand

  2021cites this paper
• Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma

  2021cites this paper
• Emerging immunotherapeutic strategies for the treatment of breast cancer

  2021cites this paper
• Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

  2021cites this paper
• Prognostic significance of OX40+ lymphocytes in tumor stroma of surgically resected small-cell lung cancer

  2021cites this paper
• Fractional Laser Treatment Boosts Systemic Anti-Tumor Immunity in Combination with OX40 Agonist and PD-1 Blockade

  2021cites this paper
• The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy

  2021cites this paper
• Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties

  2021cites this paper
• Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.

  2021cites this paper
• Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration

  2021cites this paper
• CD137+ T-Cells: Protagonists of the Immunotherapy Revolution

  2021cites this paper
• Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression

  2021cites this paper
• Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4–Targeted Immunotherapy

  2021cites this paper
• Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse

  2021cites this paper
• Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing

  2021cites this paper
• STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity

  2021cites this paper
• Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis

  2021cites this paper
• Immune-Checkpoint Inhibitors in B-Cell Lymphoma

  2020cites this paper
• Immunotherapy in hepatocellular carcinoma: Combination strategies

  2020cites this paper
• Emerging immune checkpoint inhibitors for the treatment of head and neck cancers

  2020cites this paper
• Molecular Profiling of Exceptional Responders to Cancer Therapy.

  2020cites this paper
• Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody.

  2020cites this paper
• The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma.

  2020cites this paper
• Bifunctional macromolecule activating both OX40 and interferon-α signaling displays potent therapeutic effects in mouse HBV and tumor models.

  2020cites this paper
• Steatohepatitis Impairs T cell-directed Immunotherapies Against Liver Tumors in Mice.

  2020cites this paper
• Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review

  2020cites this paper
• FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells

  2020cites this paper
• Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis

  2020cites this paper
• OX40 genetic variations in patients with breast cancer: a case-control study

  2020cites this paper
• New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials

  2020cites this paper
• Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets

  2020cites this paper
• Granzyme B PET Imaging of Immune Checkpoint Inhibitor Combinations in Colon Cancer Phenotypes

  2020cites this paper
• Elevated TNFRSF4 gene expression is a predictor of poor prognosis in non-M3 acute myeloid leukemia

  2020cites this paper
• Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways.

  2020cites this paper
• A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice

  2020cites this paper
• Overview of Basic Immunology and Clinical Application.

  2020cites this paper
• CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement

  2020cites this paper
• Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses

  2020cites this paper
• Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy

  2020cites this paper
• The adverse events associated with combination immunotherapy in cancers: Challenges and chances

  2020cites this paper
• OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity.

  2020cites this paper
• Discovery of New Immune Checkpoints: Family Grows Up.

  2020cites this paper
• Small Molecular Immune Modulators as Anticancer Agents.

  2020cites this paper
• Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy

  2020influential citation
• T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

  2020cites this paper
• Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity.

  2020influential citation
• Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association

  2020cites this paper